Mercantile Life Science Ventures and Big Idea Ventures Invest in Maia Fertility to Advance Ferizyme™ Platform
Key Insights
Mercantile Life Science Ventures IV (search) and Big Idea Ventures (search) announced a joint investment in Maia Fertility (search) to accelerate development of its Ferizyme (search)™ sustained-release enzyme platform.
The funding will expand clinical studies across commercial cattle operations in North America and Europe, building the scientific foundation for future human reproductive health applications.
Ferizyme (search)™ is designed to improve fertility in mammals through a proprietary sustained-release delivery mechanism targeting reproductive bottlenecks.
Mercantile Life Science Ventures IV (search) (MLSV) and Big Idea Ventures (search) (BIV), through its Generation Food Rural Partners fund (GFRP), have announced a joint investment in Maia Fertility (search), a biotechnology company advancing reproductive health through its proprietary sustained-release enzyme platform, Ferizyme (search)™. The announcement was made on July 30, 2026, from Rehovot, Israel and New York.
The strategic funding is intended to expand clinical studies across commercial cattle operations, establishing the scientific groundwork for eventual human medical applications. The partnership brings together MLSV's life sciences investment expertise and BIV's agricultural acceleration capabilities to drive the technology forward.
A Platform Built on Sustained-Release Enzyme Technology
Maia Fertility (search) is focused on eliminating reproductive bottlenecks through Ferizyme (search)™, a sustained-release enzyme designed to improve fertility in mammals. The company's approach represents what CEO Nir Arbel described as "a fundamental rethinking of fertility."
The investment will be deployed across three strategic priorities: advancing clinical validation through efficacy studies on commercial farms in North America and Europe, optimizing the sustained-release delivery technology for maximum success rates, and scaling market adoption within the livestock industry while simultaneously preparing healthcare infrastructure for future human applications.
Leadership Perspectives
"Ferizyme (search)™ represents a fundamental rethinking of fertility. With MLSV and BIV, we have the infrastructure to prove this technology at scale and carry that momentum into the market," said Nir Arbel, CEO of Maia Fertility (search).
Tom Mastrobuoni, Chief Investment Officer of Big Idea Ventures (search), emphasized the dual-market opportunity: "The science behind Ferizyme (search)™ is compelling, the cattle market opportunity is immediate, and the long-term pathway into human reproductive health is transformative. We're excited to accelerate what Maia Fertility (search) has built."
I. Steven Edelson, CEO of Mercantile Companies Inc., noted the cross-sector significance: "Reproductive efficiency is key to both healthcare and agriculture. Mercantile is proud to bring this technology to the farms and clinics that need it most."
Investment Structure and Partners
Big Idea Ventures (search) is a global investment firm focused on food, agriculture, and materials innovation, with more than 100 portfolio companies across 30 countries. The Generation Food Rural Partners fund is an RBIC-licensed investment fund designed to support economic growth and innovation in rural communities across the United States, backed by members of the Farm Credit System including Farm Credit Services of America, CoBank, Compeer Financial, and Mid-America Farm Credit.
Mercantile Companies Inc., headquartered in Chicago, Illinois, is a global investment firm with holdings across healthcare, wellness, agriculture, and technology/AI sectors. The firm manages a diverse international portfolio focused on long-term value creation through operational expertise and strategic market expansion.
The investment positions Maia Fertility (search) to generate clinical data from commercial cattle operations that will serve as the foundation for regulatory and clinical pathways into human reproductive medicine, though specific timelines for human trials were not disclosed.